<style face="normal" font="default" size="100%">274 Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CART cell therapy with disruptions of the TGFBR2 and Regnase-1 genes for improved manufacturing and potency</style>

Drupal-HighWire